PhaseBio Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on PhaseBio Pharmaceuticals's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M
Aug 12PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?
Aug 10
PhaseBio shares surge after inking exclusive license agreement for bentracimab
Jun 17What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?
Mar 04If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%
Jan 08PhaseBio Pharmaceuticals EPS misses by $0.15
Nov 12Revenue & Expenses BreakdownBeta
How PhaseBio Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 1 | -103 | 17 | 0 |
| 31 Mar 22 | 11 | -115 | 17 | 0 |
| 31 Dec 21 | 11 | -131 | 16 | 0 |
| 30 Sep 21 | 11 | -118 | 15 | 0 |
| 30 Jun 21 | 10 | -112 | 14 | 0 |
| 31 Mar 21 | 0 | -111 | 13 | 0 |
| 31 Dec 20 | 0 | -99 | 13 | 0 |
| 30 Sep 20 | 1 | -80 | 13 | 0 |
| 30 Jun 20 | 1 | -66 | 13 | 0 |
| 31 Mar 20 | 2 | -47 | 12 | 0 |
| 31 Dec 19 | 2 | -39 | 11 | 0 |
| 30 Sep 19 | 2 | -33 | 10 | 0 |
| 30 Jun 19 | 2 | -29 | 8 | 0 |
| 31 Mar 19 | 1 | -27 | 6 | 0 |
| 31 Dec 18 | 1 | -24 | 5 | 0 |
| 30 Sep 18 | 0 | -22 | 3 | 0 |
| 30 Jun 18 | 0 | -16 | 3 | -3 |
| 31 Mar 18 | 0 | -12 | 2 | -1 |
| 31 Dec 17 | 0 | -10 | 2 | 0 |
Quality Earnings: Insufficient data to determine if PHAS.Q has high quality earnings.
Growing Profit Margin: Insufficient data to determine if PHAS.Q's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if PHAS.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare PHAS.Q's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if PHAS.Q's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: PHAS.Q has a negative Return on Equity (0%), as it is currently unprofitable.